List view / Grid view
A $5.9 billion acquisition of biotech Iveric Bio by Astellas…
A $5.9 billion acquisition of biotech Iveric Bio by Astellas is set to accelerate development of treatments for blinding retinal diseases.
Two Big Pharma companies have announced management changes in 2023:…
Two Big Pharma companies have announced management changes in 2023: Astellas will have a new President and CEO and Bayer AG will be led by a new CEO.
Taysha will license AAV gene therapy candidates TSHA-102 for Rett…
Taysha will license AAV gene therapy candidates TSHA-102 for Rett syndrome and TSHA-120 for giant axonal neuropathy to Astellas.
Astellas and Dyno Therapeutics will develop adeno-associated virus (AAV) vectors…
Astellas and Dyno Therapeutics will develop adeno-associated virus (AAV) vectors for gene therapy directed to skeletal and cardiac muscle.
